To the Editor: The Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) study did not show the noninferiority of two moxifloxacincontaining regimens, shortened to 4 months, as compared with a control regimen, for the treatment of tuberculosis. Failures during the treatment phase occurred in less than 2% of patients. More unfavorable outcomes in the two groups with shorter regimens, as compared with the control group, were driven by more relapses after conversion to culture-negative status after the end of treatment. Relapse strains were those shown to be identical on 24-locus mycobacterial-interspersedrepetitive-unit (MIRU) analysis. First, wholegenome sequencing enables the differentiation between relapse and reinfection with greater resolution than MIRU analysis. 1 Second, differentiation between relapse and reinfection with the same strain from a close relative 2 might be impossible if the diversity of circulating clones is limited. 3 Reinfection with the same strain from a close relative can occur frequently 4 in areas with a high prevalence of tuberculosis (where this study was conducted). The results could be different in areas with a low prevalence of tuberculosis. 
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The Authors Reply: We agree that an increased dose of moxifloxacin might be of interest and has proved to be valuable in patients with limited treatment options. We aimed to register a new shortened regimen for susceptible disease, and our approach was to repurpose an existing licensed preparation at its approved dose. This strategy has the advantage that the safety charac-teristics of all the regimen components were well understood. Because the proposed 800-mg dose is outside the current license and the adverseevent profile among an unselected population is unpredictable, the incorporation of such a dose would require intensive preclinical and clinical testing before it could be used in a regulatory phase 3 study. Moreover, as shown in Table S3B in the Supplementary Appendix, available with the full text of the article at NEJM.org, patients receiving moxifloxacin who had a higher body-mass index (BMI) had a better outcome than did those with a low BMI, which argues against the supposition that a higher dose might have been successful. This result contrasts with the OFLOTUB study, in which the opposite was found. 1 Next-generation whole-genome sequencing provides increased granularity to differentiate relapse from reinfection, as we found in a subset of patients from the REMoxTB cohort. 2 Among the many sensitivity analyses that we performed, we evaluated the effect of calling all reinfections "unfavorable" (instead of "not able to be assessed"), which resulted in proportions of unfavorable outcomes of 17%, 25%, and 26% in the control, isoniazid, and ethambutol groups, respectively. Thus, this different interpretation did not alter the overall outcome of the study. Whole-genome sequencing will have an important effect on our understanding of tuberculosis infection, and these insights will have consequences for the design of clinical trials. Similarly, enumerating the number of mixed infections and improving recognition of laboratory cross-contamination could reduce sample size.
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